The U.S. Food and Drug Administration (FDA) has approved Xalkori (crizotinib) to treat patients with late-stage non-small cell lung cancers who express the abnormal anaplastic lymphoma kinase (ALK)…
Reader Survey
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.